Federal: HR7366

Bill Summary

HR7366, the Dietary Supplement Regulatory Uniformity Act, amends the Federal Food, Drug, and Cosmetic Act to establish FDA preemption over dietary supplement regulation, preventing states and localities from imposing requirements that differ from or exceed federal standards. The bill allows states and localities to seek exemptions from the Secretary of Health and Human Services for regulations that are more stringent than federal law or address compelling local conditions, provided the exemption is granted through formal regulatory process. This centralization of regulatory authority consolidates dietary supplement oversight under federal jurisdiction rather than allowing a patchwork of state and local rules. The measure essentially prevents stricter state-level dietary supplement standards unless specifically approved by HHS.

Why It Matters to MAHA

MAHA opposes HR7366 because it eliminates patient and state health freedom by centralizing regulatory power at the federal level and preventing states from enacting stronger consumer protections for dietary supplements. While MAHA supports reducing regulatory barriers to treatment access, this bill does the opposite by preventing states from requiring higher safety, purity, or transparency standards that might better serve their citizens. The exemption process creates bureaucratic hurdles and gives federal regulators veto power over state decisions designed to protect public health, contradicting MAHA's commitment to local autonomy and transparency. States and communities should retain the right to set their own standards for supplement quality and labeling without seeking federal permission, and federal preemption strips away that democratic authority.